DiscoverDr. Kara Fitzgerald | New Frontiers in Functional Medicine, Longevity, Epigeneticsp-Tau 217: The Breakthrough Biomarker Revolutionizing Early Alzheimer’s Detection
p-Tau 217: The Breakthrough Biomarker Revolutionizing Early Alzheimer’s Detection

p-Tau 217: The Breakthrough Biomarker Revolutionizing Early Alzheimer’s Detection

Update: 2025-03-19
Share

Description

Join me for a fascinating conversation around an exciting breakthrough in dementia detection that’s offering real hope for early intervention. Dr. Hans Frykman, Chief Scientific Officer at Neurocode Laboratories, is here to share groundbreaking insights into cutting-edge biomarkers that can identify pathology associated with Alzheimer's disease before symptoms even appear. What’s even more fascinating is how these same tools are revealing neuroinflammation caused by infections, including COVID, Lyme disease, and mold exposure—issues that are incredibly relevant in functional medicine today. The assays Dr. Frykman and his team have developed, and continue to research, are transforming the way we think about diagnosing and addressing neurodegeneration. We’re talking about a potential game-changer that allows us to intervene earlier, reverse damage, and ultimately improve the trajectory of these conditions. This is an extraordinary time in science and medicine, and the work we’re discussing today is at the forefront of it all. Don’t miss out on how this could reshape your practice. ~DrKF


Check out the show notes at https://tinyurl.com/2t55s3y3 for the full list of links and resources.



GUEST DETAILS


Dr. Hans Frykman, MD PhD FRCPC
hfrykman@neurocode.com


Hans Frykman MD, Ph.D., FRCPC is the founder, CEO, and medical director of BC Neuroimmunology Lab located in the UBC hospital on the University of BC campus in Vancouver BC. He is the medical director for Lykke Lab a genetics laboratory also on the University of BC campus. Also, he is the CSO for Neurocode Lab Inc. in Bellingham WA, a high-complexity, specialty lab focused on neuroimmunology and biomarkers in neurodegeneration. Dr. Frykman has a clinical faculty position at the University of British Columbia, Faculty of Medicine, Division of Neurology.


THANK YOU TO OUR SPONSORS


DIAMOND


DUTCH: https://dutchtest.com/for-providers


Biotics Research: https://www.bioticsresearch.com/


GOLD


TimeLine Nutrition: https://tinyurl.com/bdzx2xms


Vibrant Wellness: https://www.vibrant-wellness.com/


EXCLUSIVE OFFERS FROM OUR SPONSORS


OneSkin: Get 15% off OneSkin with the code DRKARA at oneskin.co/DRKARA


Try Qualia NAD+ for up to 50% off! Visit http://qualialife.com/kara15 and use code KARA15 at checkout for an additional 15% off your entire purchase!


Why MitoQ’s mitochondria-targeting is a critical step for your healthspan and longevity strategy.https://tinyurl.com/4f8t7jt6


Want more? CONNECT WITH DrKF


Join our newsletter here: https://www.drkarafitzgerald.com/newsletter/ Or take our pop quiz and test your BioAge! https://www.drkarafitzgerald.com/bioagequiz


YouTube: https://tinyurl.com/hjpc8daz


Instagram: https://www.instagram.com/drkarafitzgerald/


Facebook: https://www.facebook.com/DrKaraFitzgerald/


DrKF Clinic: Patient consults with DrKF physicians including Younger You Concierge: https://tinyurl.com/yx4fjhkb
Younger You book: https://tinyurl.com/mr4d9tym
Better Broths and Healing Tonics book: https://tinyurl.com/3644mrfw
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

p-Tau 217: The Breakthrough Biomarker Revolutionizing Early Alzheimer’s Detection

p-Tau 217: The Breakthrough Biomarker Revolutionizing Early Alzheimer’s Detection

Dr. Kara Fitzgerald